228 related articles for article (PubMed ID: 23810015)
1. Adherence rates and correlates in long-term hormonal therapy.
Dunn J; Gotay C
Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
[TBL] [Abstract][Full Text] [Related]
2. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
3. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
4. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
5. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
6. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
7. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
10. Translating trial data into patients benefits: making the right choice.
Chlebowski RT
Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
[TBL] [Abstract][Full Text] [Related]
11. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
13. [Aromatase inhibitors and arthralgia].
Nagykálnai T; Landherr L; Mészáros E
Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors and musculoskeletal symptoms.
Khanduri S; Dodwell DJ
Breast; 2008 Feb; 17(1):76-9. PubMed ID: 17822901
[TBL] [Abstract][Full Text] [Related]
15. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy for breast cancer: don't ditch the switch!
Puhalla S; Jankowitz RC; Davidson NE
J Natl Cancer Inst; 2011 Sep; 103(17):1280-2. PubMed ID: 21859987
[No Abstract] [Full Text] [Related]
17. A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.
Petit T; Dufour P; Tannock I
Endocr Relat Cancer; 2011 Jun; 18(3):R79-89. PubMed ID: 21502311
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
Dediu M; Median D; Alexandru A; Vremes G; Gal C; Gongu M
J BUON; 2009; 14(3):375-9. PubMed ID: 19810126
[TBL] [Abstract][Full Text] [Related]
19. The importance of nonpharmacogenetic factors in endocrine therapy.
McCowan C; Thompson AM
Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant treatment in hormone receptor positive breast cancer].
Streng H
MMW Fortschr Med; 2010 Oct; 152(41):37-9. PubMed ID: 21090375
[No Abstract] [Full Text] [Related]
[Next] [New Search]
